Volunteering for early phase gene transfer research in Parkinson disease

Neurology

Volumn 66, Issue 7, 2006, Pages 1010-1015

  Kim, S Y H ^a,e   Holloway, R G ^b   Frank, S ^d   Beck, C A ^c   Zimmerman, C ^b   Wilson, R ^b   Kieburtz, K ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Bioethics Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; GENE TRANSFER; HUMAN; HYPOTHESIS; MEDICAL DECISION MAKING; MEDICAL RESEARCH; OPTIMISM; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; ATTITUDE TO HEALTH; GENE THERAPY; GENETICS; HUMAN EXPERIMENT; INFORMED CONSENT; PSYCHOLOGICAL ASPECT;

ATTITUDE TO HEALTH; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMAN EXPERIMENTATION; HUMANS; INFORMED CONSENT; PARKINSON DISEASE; QUALITY OF LIFE; RISK ASSESSMENT;

EID: 33646078330     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000208925.45772.ea     Document Type: Article

References (33)

1. Cheng J, Hitt J, Koczwara B, et al. Impact of quality of life on patient expectations regarding Phase I clinical trials. J Clin Oncol 2000;18:421-428.
2. Daugherty C, Ratain M, Grochowski E, et al. Perceptions of cancer patients and their physicians involved in Phase I trials. J Clin Oncol 1995;13:1062-1072.
3. Weinfurt KP, Castel L, Li Y, et al. The correlation between patient characteristics and expectations of benefit from phase I clinical trials. Cancer 2003;98:166-175.
4. Meropol NJ, Weinfurt KP, Burnett CB, et al. Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician-patient communication. J Clin Oncol 2003;21:2589-2596.
5. Schaeffer M, Krantz D, Wichman A, Masur H, Reed E, Vinicky JK. The impact of disease severity on the informed consent process in clinical research. Am J Med 1996;100:261-268.
6. Appelbaum PS, Roth LH, Lidz CW, et al. False hopes and best data: consent to research and the therapeutic misconception. Hastings Center Report 1987;17:20-24.
7. Macklin R. The ethical problems with sham surgery in clinical research. N Engl J Med 1999;341:992-996.
8. Tuszynski MH, Thal L, Pay M, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005;11:551-555.
9. Silverberg GD, Levinthal E, Sullivan EV, et al. Assessment of low-flow CSF drainage as a treatment for AD: results of a randomized pilot study. Neurology 2002;59:1139-1145.
10. Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 2003;61:46-54.
11. Freed C, Greene P, Breeze R, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001;344:710-719.
12. Freeman TB, Watts R, Hauser RA, et al. A prospective, randomized, double-blind, surgical placebo-controlled trial of intrastriatal transplantation of fetal porcine ventral mesencephalic tissue (Neurcell-PD) in subjects with Parkinson's disease. Exp Neurol 2002;175:426.
13. Olanow C, Goetz CG, Kordower J, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003;54:403-414.
14. Nutt JGM, Burchiel K, Comella C, et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003;60:69-73.
15. Noguchi P. Risks and benefits of gene therapy. N Engl J Med 2003;348:193-194.
16. Marshall E. Gene therapy on trial. Science 2000;288:951-957.
17. Gaskin DJ, Weinfurt KP, Castel LD, et al. An exploration of relative health stock in advanced cancer patients. Med Decis Making 2004;24:614-624.
18. Folstein MF, Folstein SE, McHugh P. Mini-Mental State. A practical guide for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
19. Bennett KJ, Torrance GW, Boyle MH, Guscott R. Cost-utility analysis in depression: the McSad Utility Measure for Depression Health States. Psychiatric Services 2000;51:1171-1176.
20. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
21. Fahn S, Elton RL, members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, eds. Recent developments in Parkinson's disease. Vol. 2. Florham Park, NJ: MacMillan Healthcare Information, 1987:153-163.
22. Schwab RS, England AC. Projection technique for evaluating surgery in Parkinson's disease. In: Gillingham FJ, Donaldson IML, eds. Third Symposium on Parkinson's disease. Edinburgh: Livingstone, 1969:152-157.
23. Schrag A, Selai C, Jahanshani M, Quinn NP. The EQ-5D - a generic quality of life measure - is a useful instrument to measure quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2000;69:67-73.
24. EuroQoL Group. EuroQoL: a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
25. Jenkinson C, Peto V, Fitzpatrick R, Greenhall R, Hyman N. Self-reported functioning and well-being in patients with Parkinson's disease: comparison of the Short-form Health Survey (SF-36) and the Parkinson's Disease Questionnaire (PDQ-39). Age Ageing 1995;24:505-509.
26. Beck AT, Ward C, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-567.
27. Snaith RP, Baugh SJ, Clayden AD, Husain A, Sipple MA. The Clinical Anxiety Scale: an instrument derived from the Hamilton Anxiety Scale. Br J Psychiatry 1982;141:518-523.
28. Strull WM, Lo B, Charles G. Do patients want to participate in medical decision making? JAMA 1984;252:2990-2994.
29. Miller AJ. Subset selection in regression. Second ed. New York: Chapman and Hall, 2002.
30. Horng S, Grady C. Misunderstanding in clinical research: distinguishing therapeutic misconception, therapeutic misestimation, and therapeutic optimism. IRB: Ethics Human Res 2003;25:11-16.
31. Miller M. Phase I oncology trials. In: Amdur R, Bankert E, eds. Institutional review board: management and function. Sudbury, MA: Jones and Bartlett, 2002:465-475.
32. Horstmann E, McCabe MS, Grochow L, Yamamoto S. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 2005;352:895-904.
33. Fischhoff B, Bostrom A, Quadrel MJ. Risk perception and communication. Annu Rev Public Health 1993;14:183-203.